Immunovant to start pivotal Phase 2b in CIDP in H2 2022; Phase 2 in Graves' Disease in early 2023

Immunovant, Inc.

Pivotal Phase 2b trial of batoclimab in CIDP to start H2 2022; initial open-label results expected H1 2024.
Phase 2 trial of batoclimab in Graves' Disease to start early 2023; initial results expected H2 2023.
Batoclimab now in five indications: MG, TED, CIDP, Graves', and wAIHA (trial design pending regulator interaction later 2022).
Data readouts expected every half-year from H2 2023 through H1 2025 across multiple indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.